Scinai Immunotherapeutics Ltd. (SCNI)
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI ) Q2 2024 Results Conference Call August 20, 2024 11:00 AM ET Company Participants Liat Halpert - Head of Business Development Amir Reichman - CEO Liat Halpert Good morning, everyone.
Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) unveiled promising preclinical outcomes for its innovative anti IL-17A/F antibody fragment (NanoAb) aimed at treating mild to moderate plaque psoriasis.
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?
Scinai Immunotherapeutics (NASDAQ: SCNI ) stock is taking off on Monday after the development stage biopharmaceutical company announced results from an early study. Scinai Immunotherapeutics revealed results from an in-vivo preclinical study of anti IL-17A/F VHH antibody fragment NanoAb.
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 88% Today?
Scinai Immunotherapeutics (NASDAQ: SCNI ) stock is rocketing higher on Monday alongside heavy pre-market trading of the development-stage biopharmaceutical company's shares this morning. This has more than 7 million shares of SCNI stock changing hands as of this writing.
